newsfilter
← Latest News
Business Wire·

Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC

The Taiwan FDA approved the amended protocol and the lead Taiwan site received IRB approval during September of 2026. The next stage (Part 2) is a single-arm study enrolling never-smoker patients with the EGFR exon